Discovery of epigenetically silenced genes in acute myeloid leukemias

Leukemia

Volumn 21, Issue 5, 2007, Pages 1026-1034

  Desmond, J C ^a   Raynaud, S ^b   Tung, E ^a   Hofmann, W K ^c   Haferlach, T ^d   Koeffler, H P ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA CATENIN; ENOLASE; ENOLASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15 HOMOLOGY DOMAIN CONTAINING PROTEIN 3; GENOMIC DNA; PROTEIN ASTML; PROTEIN DRAL; PROTEIN GAS2L1; PROTEIN MX1; PROTEIN PXDN; TRANSCRIPTION FACTOR IIS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD34 SELECTION; CHROMOSOME DELETION 5; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

EID: 34247579710     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404611     Document Type: Article

References (38)

1. Jones PA. The DNA methylation paradox. Trends Genet 1999; 15 34-37.
2. Newell-Price J, Clark AJ, King P. DNA methylation and silencing of gene expression. Trends Endocrinol Metab 2000; 11: 142-148.
3. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 2003; 109: 80-88.
4. Teofili L, Martini M, Luongo M, Diverio D, Capelli G, Breccia M et al. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia 2003; 17: 919-924.
5. Guo Y, Engelhardt M, Wider D, Abdelkarim M, Lubbert M. Effects of 5-aza-2′-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells. Leukemia 2006; 20: 115-121.
6. Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003; 109: 89-102.
7. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53-61.
8. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005; 15: 169-172.
9. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
10. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11: 1-5.
11. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956-962.
12. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000; 249: 135-164.
13. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: Dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2: S24-S29.
14. Look AT. Molecular Pathogenesis of MDS. Hematology (Am Soc Hematol Educ Program) 2005, 156-160.
15. Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa 3rd R et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 2001; 71: 235-245.
16. Dann EJ, Rowe JM. Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol 2001; 14: 119-137.
17. Koeffler HP, Golde DW. Acute myelogenous leukemia: A human cell line responsive to colony-stimulating activity. Science 1978; 200 1153-1154.
18. Coura R, Prolla JC, Meurer L, Ashton-Prolla P. An alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue. J Clin Pathol 2005; 58: 894-895.
19. Takai N, Kawamata N, Walsh CS, Gery S, Desmond JC, Whittaker S et al. Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res 2005; 3: 261-269.
20. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2: 485-495.
21. Komor M, Guller S, Baldus CD, de Vos S, Hoelzer D, Ottmann OG et al. Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation. Stem Cells 2005; 23: 1154-1169.
22. Hendrich B, Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 2003; 19: 269-277.
23. Dodge JE, Munson C, List AF. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leuk Res 2001; 25: 917-925.
24. Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa 3rd R, Larson RA et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA 1997; 94: 6948-6953.
25. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005, 1-9.
26. Ishiguro A, Spirin KS, Shiohara M, Tobler A, Gombart AF, Israel MA et al. Id2 expression increases with differentiation of human myeloid cells. Blood 1996; 87: 5225-5231.
27. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005; 19: 103-111.
28. Galperin E, Benjamin S, Rapaport D, Rotem-Yehudar R, Tolchinsky S, Horowitz M. EHD3: A protein that resides in recycling tubular and vesicular membrane structures and interacts with EHD1. Traffic 2002; 3: 575-589.
29. Naslavsky N, Caplan S. C-terminal EH-domain-containing proteins: consensus for a role in endocytic trafficking, EH? J Cell Sci 2005; 118: 4093-4101.
30. Naslavsky N, Rahajeng J, Sharma M, Jovic M, Caplan S. Interactions between EHD proteins and Rab11-FIP2; A role for EHD3 in early endosomal transport. Mol Biol Cell 2006; 17: 163-177.
31. Hirst J, Borner GH, Harbour M, Robinson MS. The aftiphilin/p200/ \{gamma\}-synergin complex. Mol Biol Cell 2005; 16: 2554-2565.
32. Nakamaki T, Kawabata H, Saito B, Matsunawa M, Suzuki J, Adachi D et al. Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia. Br J Haematol 2004; 125: 42-49.
33. Staber PB, Linkesch W, Zauner D, Beham-Schmid C, Guelly C, Schauer S et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 2004; 23: 894-904.
34. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263-270.
35. Horrigan SK, Arbieva ZH, Xie HY, Kravarusic J, Fulton NC, Naik H et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000; 95: 2372-2377.
36. Nagafuchi A. Molecular architecture of adherens junctions. Curr Opin Cell Biol 2001; 13: 600-603.
37. Harris TJ, Peifer M. Decisions, decisions: Beta-catenin chooses between adhesion and transcription. Trends Cell Biol 2005; 15: 234-237.
38. Nemade RV, Bierie B, Nozawa M, Bry C, Smith GH, Vasioukhin V et al. Biogenesis and function of mouse mammary epithelium depends on the presence of functional alpha-catenin. Mech Dev 2004; 121: 91-99.